DD202019A5 - Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-oxadiazol-2-oxiden - Google Patents

Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-oxadiazol-2-oxiden Download PDF

Info

Publication number: DD202019A5
Authority: DD; German Democratic Republic
Prior art keywords: denotes; see diagramm; formula; methyl; atoms
Prior art date: 1980-12-18

Application number

DD81235739A

Other languages

German (de)

English (en)

Inventor

Karl Schoenafinger

Rudi Beyerle

Anton Mogilev

Helmut Bohn

Melitta Just

Piero A Martorana

Rolf-Eberhard Nitz

Original Assignee

Cassella Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-12-18

Filing date

1981-12-14

Publication date

1983-08-24

1981-12-14 Application filed by Cassella Ag filed Critical Cassella Ag

1983-08-24 Publication of DD202019A5 publication Critical patent/DD202019A5/de

Links

238000002360 preparation method Methods 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title claims abstract description 10
150000001875 compounds Chemical class 0.000 claims abstract description 39
239000002253 acid Substances 0.000 claims abstract description 19
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
150000001412 amines Chemical class 0.000 claims abstract description 9
125000000217 alkyl group Chemical group 0.000 claims abstract description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
150000002148 esters Chemical class 0.000 claims abstract description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 4
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims abstract description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 3
125000004429 atom Chemical group 0.000 claims abstract 2
239000002270 dispersing agent Substances 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 5
238000010992 reflux Methods 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
230000002745 absorbent Effects 0.000 claims 1
239000002250 absorbent Substances 0.000 claims 1
-1 3,4-Disubstituted 1,2,5-oxadiazole-2-oxides Chemical class 0.000 abstract description 11
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
150000003839 salts Chemical class 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
210000000748 cardiovascular system Anatomy 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 3
229960001412 pentobarbital Drugs 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
210000001147 pulmonary artery Anatomy 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
230000003257 anti-anginal effect Effects 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229950009941 chloralose Drugs 0.000 description 2
229940125890 compound Ia Drugs 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960000201 isosorbide dinitrate Drugs 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
KCMCIQNPQUSQKQ-UHFFFAOYSA-N 2-oxido-1,2,5-oxadiazol-2-ium Chemical compound [O-][N+]1=CC=NO1 KCMCIQNPQUSQKQ-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
240000001879 Digitalis lutea Species 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
208000035342 Isolated congenital onychodysplasia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000007656 barbituric acids Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960002877 dihydralazine Drugs 0.000 description 1
VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000001435 haemodynamic effect Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
QOHMWDJIBGVPIF-UHFFFAOYSA-N n',n'-diethylpropane-1,3-diamine Chemical compound CCN(CC)CCCN QOHMWDJIBGVPIF-UHFFFAOYSA-N 0.000 description 1
201000010158 nonsyndromic congenital nail disorder 7 Diseases 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
229960004923 phenprocoumon Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
239000003880 polar aprotic solvent Substances 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
238000012337 thromboprophylaxis Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1
150000003738 xylenes Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cephalosporin Compounds (AREA)
Chemical Treatment Of Metals (AREA)
Preventing Corrosion Or Incrustation Of Metals (AREA)

DD81235739A 1980-12-18 1981-12-14 Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-oxadiazol-2-oxiden DD202019A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19803047749 DE3047749A1 (de)	1980-12-18	1980-12-18	3,4-disubstituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen

Publications (1)

Publication Number	Publication Date
DD202019A5 true DD202019A5 (de)	1983-08-24

Family

ID=6119512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD81235739A DD202019A5 (de)	1980-12-18	1981-12-14	Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-oxadiazol-2-oxiden

Country Status (14)

Country	Link
EP (1)	EP0054873B1 (fr)
JP (1)	JPS57123174A (fr)
AT (1)	ATE9692T1 (fr)
AU (1)	AU7855781A (fr)
CA (1)	CA1173034A (fr)
DD (1)	DD202019A5 (fr)
DE (2)	DE3047749A1 (fr)
DK (1)	DK533781A (fr)
ES (1)	ES508087A0 (fr)
HU (1)	HU183750B (fr)
NO (1)	NO814097L (fr)
PL (1)	PL234258A1 (fr)
SU (1)	SU1152519A3 (fr)
ZA (1)	ZA818725B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4507485A (en) *	1984-01-23	1985-03-26	Bristol-Myers Company	3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
DE4217794A1 (de) *	1992-05-29	1993-12-02	Cassella Ag	Phenylfuroxane
DE4218582A1 (de) *	1992-06-05	1993-12-09	Cassella Ag	Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4218979A1 (de) *	1992-06-10	1993-12-16	Cassella Ag	Pyrimidofuroxane
DE4220264A1 (de) *	1992-06-20	1993-12-23	Cassella Ag	Phenyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4223800A1 (de) *	1992-07-20	1994-01-27	Cassella Farbwerke Mainkur Ag	Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
DE4401150A1 (de) *	1994-01-17	1995-07-20	Cassella Ag	Furazancarbonsäurederivate
US6957741B2 (en)	2001-08-07	2005-10-25	Manfred Franz Axel Freissle	Screening arrangement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH498856A (de) *	1968-02-06	1970-11-15	Geigy Ag J R	Verfahren zur Herstellung von neuen Furazanderivaten
GB1474692A (en) *	1973-05-21	1977-05-25	Ici Ltd	Furoxan production

1980
- 1980-12-18 DE DE19803047749 patent/DE3047749A1/de not_active Withdrawn
1981
- 1981-12-01 NO NO814097A patent/NO814097L/no unknown
- 1981-12-01 DK DK533781A patent/DK533781A/da not_active Application Discontinuation
- 1981-12-12 DE DE8181110400T patent/DE3166527D1/de not_active Expired
- 1981-12-12 EP EP81110400A patent/EP0054873B1/fr not_active Expired
- 1981-12-12 AT AT81110400T patent/ATE9692T1/de not_active IP Right Cessation
- 1981-12-14 DD DD81235739A patent/DD202019A5/de unknown
- 1981-12-15 PL PL23425881A patent/PL234258A1/xx unknown
- 1981-12-16 AU AU78557/81A patent/AU7855781A/en not_active Abandoned
- 1981-12-16 SU SU813367546A patent/SU1152519A3/ru active
- 1981-12-17 CA CA000392542A patent/CA1173034A/fr not_active Expired
- 1981-12-17 ES ES508087A patent/ES508087A0/es active Granted
- 1981-12-17 JP JP56202599A patent/JPS57123174A/ja active Pending
- 1981-12-17 ZA ZA818725A patent/ZA818725B/xx unknown
- 1981-12-18 HU HU813860A patent/HU183750B/hu unknown

Also Published As

Publication number	Publication date
NO814097L (no)	1982-06-21
ES8300102A1 (es)	1982-10-01
ES508087A0 (es)	1982-10-01
EP0054873B1 (fr)	1984-10-03
DK533781A (da)	1982-06-19
AU7855781A (en)	1982-06-24
CA1173034A (fr)	1984-08-21
DE3047749A1 (de)	1982-07-22
HU183750B (en)	1984-05-28
ZA818725B (en)	1982-11-24
EP0054873A1 (fr)	1982-06-30
PL234258A1 (fr)	1982-08-02
ATE9692T1 (de)	1984-10-15
JPS57123174A (en)	1982-07-31
SU1152519A3 (en)	1985-04-23
DE3166527D1 (en)	1984-11-08

Publication	Publication Date	Title
DE2734070C2 (de)	1983-12-29	Aminoalkylfuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2354389C2 (de)	1982-07-15	2-(4-Acyl-homopiperazino)-4-amino-6,7-dimethoxy-chinazolin-Verbindungen und Verfahren zu ihrer Herstellung
AT363096B (de)	1981-07-10	Verfahren zur herstellung von neuen phthalazinderivaten und deren salzen
DE2657013A1 (de)	1977-07-28	Phthalanderivate und verfahren zu deren herstellung sowie diese enthaltende pharmazeutische mittel
DE19540995A1 (de)	1997-05-07	Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0059356A1 (fr)	1982-09-08	Amino-3-sydnone imines substitués, procédé pour leur préparation et leur application
DE2830884C2 (fr)	1990-01-11
DD202019A5 (de)	1983-08-24	Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-oxadiazol-2-oxiden
EP0054872B1 (fr)	1984-10-31	Oxadiazole-1,2,5 oxydes-2 bis-substitués en position 3 et 4, leur procédé de préparation, et compositions pharmaceutiques les contenant
DE2410938A1 (de)	1974-09-19	Chinazolinderivate und diese enthaltende arzneimittel
DE3319956A1 (de)	1984-12-06	1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4328352A1 (de)	1995-03-02	Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0279283A2 (fr)	1988-08-24	Dérivés de pyridazinone
DE2805167A1 (de)	1978-08-10	Entzuendungshemmende imidazole, verfahren zu ihrer herstellung und sie entheltende arzneimittel
EP0030343A1 (fr)	1981-06-17	Amino-2 dihydro-3,4-pyridines substituées, procédé pour leur préparation et utilisation comme médicaments
DD209195A5 (de)	1984-04-25	Verfahren zur herstellung von 1,2,5-oxadiazol-3,4-dicarbonsaeurederivaten
DE3122540A1 (de)	1982-03-25	In 3-stellung substituierte 2-propenimidamide und verfahren zu deren herstellung
EP0338352A2 (fr)	1989-10-25	Dérivés d'acide salicylique
EP0790245A1 (fr)	1997-08-20	Guanidides d'acides alcénylcarboxiliques substituée par un groupe thiophényl, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
DD142875A5 (de)	1980-07-16	Verfahren zur herstellung von 2-aminoaethanolderivaten
DE2760097C2 (fr)	1989-08-17
DD275241A5 (de)	1990-01-17	Verfahren zur herstellung von neuen 1-aryloxy-3-amimo-2-propanolen
DE2062055A1 (de)	1971-06-24	Propanolamin Derivate
EP0030688A2 (fr)	1981-06-24	Dérivés de pipéridine d'esters de l'acide 3-hydroxy-thiophène-2-carboxylique, leur préparation et préparations pharmaceutiques les contenant
EP0199323A2 (fr)	1986-10-29	4-Amino substitué alcoylidène-3-aryl-5(4H) isoxazolones, procédé de préparation, médicaments les contenant et leur utilisation